- Healthy Extracts Inc. engages in proprietary R&D, sales and distribution of health products through its BergaMet North America and Ultimate Brain Nutrients (“UBN”) subsidiaries
- The global brain health supplements, UBN’s domain, is projected to grow at a CAGR of 8% from 2021 to 2028
- The global heart health supplements market, BergaMet’s segment, is expected to witness a CAGR of 4.5% from 2020 to 2030
- Overall, the global botanical and plant-derived drug market will potentially expand at a CAGR of 6.1% from 2017 to 2022
According to projections by various research firms, the global health products market is expected to continue growing well into the late 2020s. The studies cite increased interest among consumers who are now adopting preventive care to help them maintain a healthy life, with higher availability of health products for the specific needs of consumers, and the ease with which they can access the said products, as some of the factors behind the growth.
The latter two growth drivers touch on the operations and focus of Healthy Extracts (OTCQB: HYEX), which serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.
Meanwhile, the increasing interest, which has led to more demand for the products, has positively impacted HYEX, as evidenced by the company’s improved revenue from $748,377 in 2019 to $1,276,559 in 2020, representing a 71% jump.
In its financial report, Healthy Extracts attributed this growth to the transition to its new business selling health nutrition products (https://ibn.fm/B0tjO). A look at the projections given by various research firms foreshadows an equally impressive future for HYEX.
A report by Grand View Research, Inc shows that the global brain health supplements market is projected to reach $13.38 billion by 2028, marking a CAGR of 8.0% from 2021 to 2028. Moreover, the plant-based segment of this market is expected to witness the fastest CAGR of 9.2% during the same period. The firm attributes this projected growth to the COVID-19 pandemic, which has made mental illnesses more prevalent, consequently boosting demand for health supplements, and the rising interest regarding mental health (https://ibn.fm/he5iD).
Brain health supplements are the domain of Ultimate Brain Nutrients (“UBN”), one of HYEX’s wholly owned subsidiaries acquired in 2020. UBN develops unique, plant-based superior proprietary health technology neuro-products that enhance the brain’s overall health by improving memory, cognition, focus and neuro-energy. As the neuro health products market continues to grow, UBN is advancing its position to meet the rising consumer demand through its unique brain health formulations.
Similarly, the heart health supplements market is expected to exceed $14 billion in 2030, growing at a CAGR of 4.5% from 2020, according to Persistence Market Research (“PMR”) (https://ibn.fm/ntYHV). Through one of its analysts, PMR observed that plant-based products were gaining more popularity and acceptance in the nutraceutical industry, and subsequently the heart health products market. This signals that conditions are favorable for HYEX’s second subsidiary, BergaMet North America (“NA”), to thrive.
BergaMet NA sells and distributes a full line of proprietary product formulations derived from the rare Citrus Bergamot SuperFruit(TM) called “bergamot,” which is native to Southern Italy. Bergamot is uniquely loaded with various antioxidant polyphenols and flavonoids, meaning that it supports and promotes overall wellness specific to cholesterol, cardiovascular and metabolic health with no known side effects.
Overall, the global botanical and plant-derived drug market, valued at $29.4 billion in 2017, is expected to reach an estimated $39.6 billion by 2022, representing a CAGR of 6.1% (https://ibn.fm/o5YRR), while the plant-based food market is expected to grow at a CAGR of 11.9% from 2020, reaching $74.2 billion in 2027 (https://ibn.fm/sdaVH).
Healthy Extracts, which is keen on developing natural plant-based formulations, is well-positioned to leverage its growing portfolio and the burgeoning health products market to continue its upward revenue growth through the remainder of this decade and beyond.
For more information, visit the company’s website at www.HealthyExtractsInc.com.
NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX
About Healthy Extracts Inc.
“Live Life Young Again”
Healthy Extracts Inc. (OCTQB: HYEX) serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.
Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM) the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents – two issued and four pending.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on April 1, 2020, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.